Non-alcoholic fatty liver disease (NAFLD) is one cause of a fatty liver, occurring when fat is deposited (steatosis) in the liver NOT due to excessive alcohol use.
It is related to insulin resistance and the metabolic syndrome and may respond to treatments originally developed for other insulin-resistant states (e.g. diabetes mellitus type 2) such as weight loss, metformin and thiazolidinediones.
Non-alcoholic steatohepatitis (NASH) is the most extreme form of NAFLD, and is (...)
humpath.com supports the 2015 edition of the European Symposium of Biopathology, June 2015 in Paris, France.
Most recent articles
EBV-associated cytotoxic T-cell lymphoma of lymph nodes; nodal EBV-positive cytotoxic T-cell lymphoma; nodal EBV cytotoxic T-cell lymphoma
apperance (#25634749#). centroblastoid appearance (56%) (lower incidence in ENKTL :15%). pleomorphic appearance ( 23%) (ENKTL : 67%).
T-cell lineage (85%) on the basis of TCR expression and/or TCRγ gene rearrangement (#25634749#). 46% are TCRβ positive (αβ T) 13% are TCRγ and/or δ positive (γδ T) 26% are TCR-silent type with clonal TCRγ gene (...)
IHC for IDH1-R132H is relatively sensitive and specific, but there is a discordance rate that is not trivial, with NGS mutation profiling. In addition, a significant proportion of patients harbor IDH1 non-R132H mutations not detectable by IHC, potentially limiting utility of IHC screening for IDH1 mutations.
Comparison of Next-generation Sequencing Mutation Profiling With BRAF and IDH1 Mutation-specific Immunohistochemistry. Jabbar KJ, Luthra R, Patel KP, Singh RR, Goswami R, (...)
IHC for BRAF V600E is relatively sensitive and specific, but there is a discordance rate that is not trivial with NGS mutation profiling. In addition, a significant proportion of patients harbor BRAF non-V600E not detectable by IHC, potentially limiting utility of IHC screening for BRAF mutations. (#25634750#)
Comparison of Next-generation Sequencing Mutation Profiling With BRAF and IDH1 Mutation-specific Immunohistochemistry. Jabbar KJ, Luthra R, Patel KP, Singh RR, Goswami (...)
3 beta 7 AAD 11A1 14-3-3sigma 15-PGDH 45M1
A A beta 42 abl acid phosphatase ACSM1 actin-general actin-alpha cardiac actin-alpha smooth muscle actin-muscle specific AE1/AE3 (cytokeratin) AF4 AGR2 AKT1 albumin alcian blue ALK alkaline phosphatase ALL1 alpha-1-antichymotrypsin alpha-1-antitrypsin alpha-fetoprotein alpha-lactalbumin AMACR AML1 androgen receptor APC API2-MALT1 Apolipoprotein D arginase1 ATM
B72.3 - bcl1 - bcl2 bcl6 bclXl bcr-abl Beclin1 BerEP4 (...)
Tumor budding is a well-established adverse prognostic factor in colorectal cancer.
colorectal carcinoma Tumor budding is a well-established adverse prognostic factor in colorectal cancer.
pancreatic ductal adenocarcinoma Tumor Budding Is an independent adverse prognostic factor in pancreatic ductal adenocarcinoma. (#25634751#) The assessment of budding with H&E is reliable and could be used to better risk stratify patients with pancreatic ductal adenocarcinoma. (...)
Lymphoepithelioma-like hepatocellular carcinoma (LEL-HCC) is an uncommon variant of HCC with only 22 cases reported in the literature in 2014.
LEL-HCC is an independent prognostic factor for overall and progression-free survivals.
LEL-HCC does not differ in frequencies of microsatellite instability, BRAF mutation, and DNA hypermethylation.
LEL-HCC is a distinct uncommon variant of HCC characterized by dense cytotoxic T-cell infiltration and favorable prognosis.
SMARCB1-deficient Vulvar Neoplasms
Loss of expression of the SMARCB1 (INI1/BAF47/SNF5) tumor-suppressor protein, originally identified in pediatric malignant rhabdoid tumors, has been noted in significant percentages of epithelioid sarcomas of classical and proximal-type and in myoepithelial carcinomas.
Epithelioid sarcoma and myoepithelial carcinoma are very rare in the vulvar region, and few of these cases have been evaluated for SMARCB1 protein loss by immunohistochemistry (IHC) or for (...)
There is strong evidence supporting an association of Classical Hodgkin lymphoma (CHL) with EBV. There is strong evidence between an altered EBV humoral immune response and development of CHL.
In epidemiologic studies the overall prevalence of EBV in CHL in immune competent individuals is approximately 50% (40-70%) with higher incidence in African and South American countries and lower incidence in some European countries. In HIV infected individuals EBV associated HL can (...)
Epstein-Barr Virus Positive Diffuse Large B Cell Lymphoma (EBV+ DLBCL) Of The Elderly; Senile EBV Lymphoproliferative Disorder
Definition: EBV-positive DLBCL of the elderly is a diagnosis that was recently added as a new category of lymphoma in the 2008 WHO Classification Tumours of Haematopoietic and Lymphoid Tissues, as a provisional clinicopathological entity.
Given the poor prognosis (mean survival: 2 years), the diagnosis of EBV-positive DLBCL must be clearly determined, and a (...)